Overview
Immumem Therapeutics Corp (pronounced ih-MYOO-mem) is revolutionizing cancer treatment by harnessing the power of immunological memory through next-generation cell-based therapies. Our pioneering regenerative medicine platform utilizes induced pluripotent stem cells (iPSCs) to engineer T and NK cells that are not only highly effective against resistant tumors but also provide durable, long-lasting immune surveillance. This innovative approach offers the promise of preventing cancer relapse with improved safety and consistency compared to conventional therapies.
The company’s name, Immumem, is derived from Immunological memory, highlighting our core focus on harnessing immune memory- the body’s natural mechanism that enables certain vaccines to provide lifelong protection after just one shot- empowering our therapies to remember and rapidly respond to cancer cells, thereby ensuring sustained defense against disease recurrence.
Our Mission
At Immumem Therapeutics, we are redefining the future of oncology with our pioneering iPSC-derived cell therapy platform. Driven by innovation and scientific excellence, our mission is to harness the transformative potential of immunological memory to deliver life-changing therapies. By targeting even the most refractory cancer types, we aim to provide patients with new hope and significantly improved outcomes, paving the way for a revolution in cancer treatment and care.
Our Expertise
Our team consists of leading scientists a strong track record of pioneering T and NK cell therapies against cancer and infectious diseases. With over a decade of groundbreaking research experience in immunological memory, Immumem has developed a top-tier regenerative medicine platform to generate best-in-class cell therapeutics that combat cancer relapse effectively.
Our Science
Immumem Therapeutics leverages immunological memory principles to prevent cancer relapse through two proprietary platforms: ImmuveilX for cellular programming and CellTellect for iPSC-derived cell manufacturing.
Core Scientific Principle
Immumem’s approach is based on immunological memory, the same mechanism that makes vaccines effective against infectious diseases. Unlike natural immune responses that often fail against cancer due to rapid T cell exhaustion and tumor immune evasion, Immumem creates engineered memory T and NK cells that function as a “cellular vaccination” against cancer relapse.
ImmuveilXTM Platform
The ImmuveilX platform combines advanced cell biology programming with precision small molecule enhancement to create memory “super-cells”. This breakthrough addresses three critical limitations of current immunotherapies:
CellTellectTM Platform
The CellTellect platform generates multi-gene edited T and NK cells from induced pluripotent stem cells (iPSCs) rather than patient blood cells. This approach provides several advantages:
Mechanism of Action
These engineered memory cells establish long-term surveillance networks capable of detecting single cancer cells that escape initial treatment. By recapitulating vaccination principles – antigen specificity, exhaustion resistance, and lasting cellular reservoirs – the platform shifts from high relapse rates to sustained anti-tumor vigilance for both immediate suppression and long-term relapse prevention.
Immunological memory, a vital defense mechanism, allows the immune system to recognize and combat recurring threats quickly. At Immumem Therapeutics, we leverage this powerful ability to enhance the effectiveness of cell therapy against cancer cells, providing an innovative and affordable solution to prevent relapse and improve patient outcomes.
Our platform enables us to engineer T and NK cells from iPSC lines, train them to target tumor cells, and create a lasting ‘memory’ that enables them to go beyond controlling the initial tumor load by attacking aggressive cancer cells if they relapse. This results in durable immunological surveillance, ensuring the injected memory T and NK cells always remember the cancer and remain vigilant against recurrence.
| Candidate | Indication | Development Stage |
|---|---|---|
| IMT-101 | Pancreatic Ductal Adenocarcinoma (PDAC) | Early Discovery |
| IMT-102 | High-Grade Serous Ovarian Carcinoma | Early Discovery |
| IMT-103 | Undisclosed | Early Discovery |
| IMT-104 | Undisclosed | Early Discovery |